Monitor upcoming clinical data readouts for KT-621 in mid-2027 (atopic dermatitis) and late-2027 (asthma), and KT-579 data in 2H26. The increased R&D spend with declining collaboration revenue suggests the company is prioritizing pipeline advancement over near-term profitability.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $95.03entry
- T+1 · 9mo ago −3.87%α −3.42% · $91.35
- T+5 · 9mo ago −12.11%α −10.98% · $83.52
- T+20 · 8mo ago −15.63%α −9.22% · $80.18
- T+60 · 6mo ago −15.17%α −22.92% · $80.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kymera Therapeutics reported financial results for Q4 and full year 2025, highlighted by a $692 million equity raise, pipeline progress including initiation of Phase 2b trials for KT-621 in atopic dermatitis and asthma, and a new Chief Development Officer appointment. The company ended 2025 with $1.6 billion in cash, providing runway into 2029.
Key Financial Metrics
Key Facts
- Collaboration revenue declined 16.7% YoY to $39.2 million in 2025
- R&D expenses increased 31.8% YoY to $316.6 million in 2025
- Net loss widened to $311.4 million in 2025 from $223.9 million in 2024
- Completed $692 million equity offering in December 2025
- Cash balance of $1.6 billion as of December 31, 2025, providing runway into 2029
- Initiated dosing in KT-579 Phase 1 trial and expanded KT-621 Phase 2b trials
Financial Impact
Revenue decreased by $7.9 million YoY while R&D spending increased by $76.4 million, resulting in a $87.5 million wider net loss. The $692 million capital raise significantly strengthened the balance sheet.
Risk Factors
- Continuing reliance on external funding as collaboration revenue declines
- High R&D spending with no near-term commercial products
- Clinical trial risks for KT-621 and KT-579 programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073386 |
| Document: kymr-20260226.htm | 0001193125-26-073386 |
| Document: 0001193125-26-073386-index-headers.html | 0001193125-26-073386 |
| Document: 0001193125-26-073386-index.html | 0001193125-26-073386 |
| Document: 0001193125-26-073386.txt | 0001193125-26-073386 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers